Quels nouveaux médicaments a l'horizon pour te traitement du cancer avancé de la prostate [New drugs at the horizon for men with prostate cancer]


Autoria(s): Shabafrouz K.; Bauer J.; Berthold D.R.
Data(s)

2010

Resumo

Despite major progress in the understanding of biological mechanisms underlying metastatic prostate cancer, the treatment of men with advanced prostate cancer remains challenging. Several randomized controlled trials with promising or positive results are underway or just released. Here we discuss new treatments which might be used in clinic in the near future: hormonal treatments (Abiraterone and MDV3100), a new chemotherapy (Cabazitaxel), a cellular vaccine (Sipuleucel-T), anti-angiogenic drugs (Bevacizumab, Aflibercept), a new radioactive treatment (Alpharadin) and a new bone-protective agent (Deno-sumab).

Identificador

http://serval.unil.ch/?id=serval:BIB_944AB2211326

isbn:1660-9379[print], 1660-9379[linking]

pmid:20564864

Idioma(s)

fr

Fonte

Revue Médicale Suisse, vol. 6, no. 250, pp. 1057-1061

Palavras-Chave #Antineoplastic Agents/pharmacology; Antineoplastic Agents/therapeutic use; Humans; Male; Prostatic Neoplasms/drug therapy
Tipo

info:eu-repo/semantics/article

article